Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure

Pharmacology and Therapeutics

Volumn 139, Issue 3, 2013, Pages 405-411

  Pretto, Francesca ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

IL2; Immunocytokines; Ipilimumab; Melanoma; Vemurafenib

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AMP 224; BEVACIZUMAB; DACARBAZINE; DARLEUKIN; IPILIMUMAB; MDX 1105; MK 3475; MPDL 3280A; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NIVOLUMAB; PACLITAXEL; PIDILIZUMAB; RITUXIMAB; SELUMETINIB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA; FEVER; HUMAN; IMMUNOGENICITY; INFLAMMATION; KIDNEY CARCINOMA; MAXIMUM TOLERATED DOSE; METASTATIC MELANOMA; MONOTHERAPY; MOTOR NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SKIN CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR REGRESSION;

CTLA-4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DTIC; EDB; ERK; EXTRA-DOMAIN B OF FIBRONECTIN; EXTRACELLULAR-SIGNAL-REGULATED KINASES; GM-CSF; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IFN-Α; IL-2; IL2; IMMUNOCYTOKINES; INTERFERON-Α; INTERLEUKIN-2; IPILIMUMAB; MAPK; MAXIMUM TOLERATED DOSE; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MTD; PD-1R; PD-L1 AND 2; PHOSPHATIDYLINOSITOL 3-KINASES; PI3K; PROGRAMMED CELL DEATH 1 LIGAND 1 AND 2; PROGRAMMED DEATH-1 RECEPTOR; VEMURAFENIB;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 84881239572     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.05.006     Document Type: Review

References (61)

1. A.E. Aplin, F.M. Kaplan, and Y. Shao Mechanisms of resistance to RAF inhibitors in melanoma J Invest Dermatol 131 2011 1817 1820
2. U. Banerji, D.R. Camidge, H.M. Verheul, R. Agarwal, D. Sarker, and S.B. Kaye The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer Clin Cancer Res 16 2010 1613 1623
3. R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, and M. Leiba Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 2008 3044 3051
4. L. Borsi, E. Balza, M. Bestagno, P. Castellani, B. Carnemolla, and A. Biro Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int J Cancer 102 2002 75 85
5. B. Carnemolla, L. Borsi, E. Balza, P. Castellani, R. Meazza, and A. Berndt Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix Blood 99 2002 1659 1665 (Pubitemid 34533039)
6. P. Castellani, G. Viale, A. Dorcaratto, G. Nicolo, J. Kaczmarek, and G. Querze The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis Int J Cancer 59 1994 612 618 (Pubitemid 24358583)
7. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
8. A. Daud, C. Soon, R. Dummer, A.M. Eggermont, W.J. Hwu, and J.J. Grob Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma Expert Opin Biol Ther 12 2012 1087 1099
9. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 (Pubitemid 34716871)
10. T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, and A. Pflugfelder A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma Clin Cancer Res 17 2011 7732 7742
11. B. Elsadek, and F. Kratz Impact of albumin on drug delivery - new applications on the horizon J Control Release 157 2012 4 28
12. P.A. Erba, M. Sollini, E. Orciuolo, C. Traino, M. Petrini, and G. Paganelli Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies J Nucl Med 53 2012 922 927
13. G.S. Falchook, K.D. Lewis, J.R. Infante, M.S. Gordon, N.J. Vogelzang, and D.J. Demarini Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol 13 2012 782 789
14. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
15. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
16. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
17. C. Garbe, K. Peris, A. Hauschild, P. Saiag, M. Middleton, and A. Spatz Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur J Cancer 46 2010 270 283
18. C. Garbe, K. Peris, A. Hauschild, P. Saiag, M. Middleton, and A. Spatz Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2012 Eur J Cancer 48 2012 2375 2390
19. A.G. Gilmartin, M.R. Bleam, A. Groy, K.G. Moss, E.A. Minthorn, and S.G. Kulkarni GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin Cancer Res 17 2011 989 1000
20. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, and P. Bhar Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 2005 7794 7803 (Pubitemid 46657376)
21. J.G. Greger, S.D. Eastman, V. Zhang, M.R. Bleam, A.M. Hughes, and K.N. Smitheman Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol Cancer Ther 11 2012 909 920
22. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
23. E.M. Hersh, S.J. O'Day, J. Powderly, K.D. Khan, A.C. Pavlick, and L.D. Cranmer A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma Invest New Drugs 29 2011 489 498
24. E.M. Hersh, S.J. O'Day, A. Ribas, W.E. Samlowski, M.S. Gordon, and D.E. Shechter A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma Cancer 116 2010 155 163
25. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
26. J.C. Hu, R.S. Coffin, C.J. Davis, N.J. Graham, N. Groves, and P.J. Guest A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor Clin Cancer Res 12 2006 6737 6747 (Pubitemid 44876843)
27. N.K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R.L. Theriault, and E. Rivera Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 2002 1038 1044 (Pubitemid 34517637)
28. N.K. Ibrahim, B. Samuels, R. Page, D. Doval, K.M. Patel, and S.C. Rao Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J Clin Oncol 23 2005 6019 6026
29. J.R. Infante, L.A. Fecher, G.S. Falchook, S. Nallapareddy, M.S. Gordon, and C. Becerra Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 13 2012 773 781
30. M. Johannsen, G. Spitaleri, G. Curigliano, J. Roigas, S. Weikert, and C. Kempkensteffen The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma Eur J Cancer 46 2010 2926 2935
31. H.L. Kaufman, and S.D. Bines OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma Future Oncol 6 2010 941 949
32. H.L. Kaufman, D.W. Kim, G. DeRaffele, J. Mitcham, R.S. Coffin, and S. Kim-Schulze Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol 17 2010 718 730
33. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704 (Pubitemid 351600389)
34. H.H. Kirchner, J. Atzpodien, and H. Poliwoda Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a Med Klin (Munich) 91 Suppl. 3 1996 44 49
35. S.S. Legha, S. Ring, A. Bedikian, C. Plager, O. Eton, and A.C. Buzaid Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha Ann Oncol 7 1996 827 835 (Pubitemid 26345874)
36. B.L. Liu, M. Robinson, Z.Q. Han, R.H. Branston, C. English, and P. Reay ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties Gene Ther 10 2003 292 303 (Pubitemid 36305598)
37. P. Lui, R. Cashin, M. Machado, M. Hemels, P.K. Corey-Lisle, and T.R. Einarson Treatments for metastatic melanoma: synthesis of evidence from randomized trials Cancer Treat Rev 33 2007 665 680 (Pubitemid 350082665)
38. J. Mangana, M.P. Levesque, M.B. Karpova, and R. Dummer Sorafenib in melanoma Expert Opin Investig Drugs 21 2012 557 568
39. D.W. Nyman, K.J. Campbell, E. Hersh, K. Long, K. Richardson, and V. Trieu Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J Clin Oncol 23 2005 7785 7793 (Pubitemid 46657375)
40. S.J. O'Day, M. Maio, V. Chiarion-Sileni, T.F. Gajewski, H. Pehamberger, and I.N. Bondarenko Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol 21 2010 1712 1717
41. R.V. Parry, J.M. Chemnitz, K.A. Frauwirth, A.R. Lanfranco, I. Braunstein, and S.V. Kobayashi CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol Cell Biol 25 2005 9543 9553 (Pubitemid 41507854)
42. 124I-L19SIP dosimetric PET study Cancer Immunol Res 2013 10.1158/2326-6066.CIR-13-0007
43. C. Robert, L. Thomas, I. Bondarenko, S.M. O'Day, D. J., and C. Garbe Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
44. M. Santimaria, G. Moscatelli, G.L. Viale, L. Giovannoni, G. Neri, and F. Viti Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer Clin Cancer Res 9 2003 571 579 (Pubitemid 36182586)
45. S. Sauer, P.A. Erba, M. Petrini, A. Menrad, L. Giovannoni, and C. Grana Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Blood 113 2009 2265 2274
46. C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, and E. Trachsel Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood 113 2009 2275 2283
47. T. Shimizu, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, and L.S. Smith The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer Clin Cancer Res 18 2012 2316 2325
48. R. Siegel, C. Desantis, K. Virgo, K. Stein, A. Mariotto, and T. Smith Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241
49. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
50. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
51. F.O. Smith, S.G. Downey, J.A. Klapper, J.C. Yang, R.M. Sherry, and R.E. Royal Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines Clin Cancer Res 14 2008 5610 5618
52. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
53. L. Tarli, E. Balza, F. Viti, L. Borsi, P. Castellani, and D. Berndorff A high-affinity human antibody that targets tumoral blood vessels Blood 94 1999 192 198 (Pubitemid 29300149)
54. B.M. Tijink, L.R. Perk, M. Budde, M. Stigter-van Walsum, G.W. Visser, and R.W. Kloet (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy Eur J Nucl Med Mol Imaging 36 2009 1235 1244
55. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
56. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
57. P. Waterhouse, J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, and K.P. Lee Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 1995 985 988
58. J.S. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, and M. Yellin Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
59. B. Weide, T.K. Eigentler, A. Pflugfelder, U. Leiter, F. Meier, and J. Bauer Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up Cancer Immunol Immunother 60 2011 487 493
60. T.C. Yeh, V. Marsh, B.A. Bernat, J. Ballard, H. Colwell, and R.J. Evans Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 13 2007 1576 1583 (Pubitemid 46450450)
61. X.P. Zhou, O. Gimm, H. Hampel, T. Niemann, M.J. Walker, and C. Eng Epigenetic PTEN silencing in malignant melanomas without PTEN mutation Am J Pathol 157 2000 1123 1128